Gastric erosions are frequently seen through the gastroendoscope. A peculiar form of erosive gastritis was described under the name 'gastritis erosiva ' by Henning and Schatzki in 1933 .' Since then, many reports have been published under such headings as 'varioliform gastritis', 'verrucous gastritis', 'octopus-sucker gastritis', 'gastritis ulcerosa et erosiva', 'complete erosion', and 'mature erosion'. ' The pathogenesis of these gastric erosions, however, is still unknown. This disease is frequently associated with duodenal ulcer.34 Moreover, Nesland and Berstad3 recently, reported that cimetidine was effective in healing gastric erosions. These findings indicate that high acid production may be closely related to the pathogenesis of erosive gastritis.
Pirenzepine is a tricyclic compound developed in West Germany for treatment of peptic ulcers. Acute or chronic treatment with pirenzepine reduces basal and stimulated acid output." Therefore, it seemed likely that pirenzepine is effective in the treatment of erosive gastritis. To test this possibility, we examined endoscopically the extent of the acid secreting areas in patients with erosive gastritis, and the healing effects of pirenzepine. On the basis of the description by Whitehead et al," the mucosa was classified as oxyntic or pyloric. When only intestinal metaplasia was apparent, the specimens were identified as 'undetermined'. As described by Vilardell,"' atrophic changes of the gastric mucosa were classified histologically as follows: (1) Superficial gastritis; (2) Atrophic gastritis; and (3) Gastric atrophy.
Patients diagnosed as having erosive gastritis were considered for the study, provided they were within the age range 19-72 years. Patients with ulcer or healed ulcer and other localised lesions in the stomach and duodenum were excluded from consideration. Informed consent was obtained from all patients, and the study was carried out in accordance with the Declaration of Helsinki.
Forty three patients who met the entry criteria were randomly assigned in a double blind fashion to pirenzepine (25 mg four times daily before each meal and at bedtime) or placebo. The Table 1 summarises the data on biopsy findings in discoloured and non-discoloured areas. All specimens collected from discoloured areas were found histologically to be normal oxyntic gland mucosa, with no fundal gastritis or pyloric mucosa. In contrast, non-discoloured areas were of either pyloric mucosa or oxyntic mucosa altered by atrophic gastritis or gastric atrophy. Therefore, by this test, the oxyntic gland areas can be identified as discoloured. BIOPSY Relationship oferosive gastritis to the acid secreting area and intestinal inetaplasia Table 4 summarises the results on the distribution of intestinal metaplasia in patients with and without erosive gastritis. Patients with erosive gastritis were significantly less frequently associated with a diffuse intestinal metaplasia. Diffuse intestinal metaplasia was seen in 14 (21.2%) in control patients, but in only three (7.0%) in patients with erosive gastritis. Table 5 summarises the data on the healing of erosive gastritis in patients treated with pirenzepine or placebo. All patients were subjected to reexamination at three months after the start of treatment.
HEALING OF EROSIVE GASTRITIS
Of 20 patients treated with pirenzepine, crater like erosions disappeared in 13 patients (65.0%). In contrast, erosions disappeared only in six of 23 (26 1%) patients who had been treated with placebo-(p<0-05). During the observation period, no change in the extent of the acid secreting areas and the distribution of intestinal metaplasia was found in all patients. Table 6 shows that the patients in the two groups 
(I(N))
Diffcrcncc betwcn the incidcnces of aibsencc of intcstinal mctaplasia in control paiticnts and paiticnts with crosivc gastritis was statistically significaint at p<0(05. For this analysis. two grades of intcstinal metaplasia werc used: abscnt versus locailised and diffusc. did not differ significantly with respect to sex distribution, age, proportion of cigarette smokers and alcohol drinkers.
Discussion
The pathogenesis of erosive gastritis is unknown. Karvonen' reported that maximum acid output (MAO) in patients with active erosions was significantly higher than in controls. Nesland and Berstad,' In the present study, we found that, by the endoscopic Congo red-methylene blue test, erosive gastritis was significantly more frequently associated with large acid secreting areas than control patients. In our study, control patients consisted not of healthy subjects but of patients who had been suspected of having gastrointestinal diseases but who were found to be normal on gastroduodenal endoscopic examination. Our findings confirmed a previous report that little or no atrophic gastritis is detected in patients with erosive gastritis.' We previously reported a close correlation between the extent of acid secreting areas and acid production.7 In general, the more extensive the acid secreting areas, the higher the acid production. Therefore, it seems likely that high acid production may be closely related to the pathogenesis of erosive gastritis.
Nesland and Berstads reported that, in a randomised double blind placebo controlled study of 100 patients with non-ulcer dyspepsia and grade 2 or 3 erosive prepyloric changes, cimetidine was significantly superior to placebo in reducing the grade of erosive prepyloric changes at reendoscopy after four weeks. In the present study, we found that complete healing of erosive gastritis was significantly more frequent in the pirenzepine treated group than in the control group three months after the start of treatment. Cimetidine also significantly reduced epigastric pain after two weeks' treatment, but did not significantly alter any histological features in the specimens from the prepyloric mucosa.'1. Vilardell,' however, reported that gastroscopic improvement may be associated with a diminution of the inflammatory infiltrates. Sata'4 also reported that erosions that were reversible and disappeared histologically consisted of foveolar hyperplasia and inflammatory infiltrates. In the present work we found no change in the extent of the acid secreting area during three months' observation period. Therefore, it is highly questionable whether cimetidine or pirenzepine can prevent recurrence of gastric erosions, and further investigations are required.
Andre et al" I reported that the improvement of endoscopic features of diffuse varioliform gastritis and immunohistochemical measurements of IgE cells in the mucosa was significantly greater in patients given the mast cell stabilising agent sodium cromoglycate than in those given cimetidine or placebo. They concluded that the disease may have an allergic basis, or at least that type 1 hypersensitivity plays some part in the pathogenesis of the disease and so diffuse varioliform gastritis must be separated from antral varioliform gastritis. In the present study, most of the lesions were located in the antrum or the angulus. We found that pirenzepine was effective for treatment of erosive gastritis in the antrum or the angulus. 
